Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SAPHNELO® safely and effectively. See full prescribing information for SAPHNELO.SAPHNELO (anifrolumab-fnia) injection, for intravenous, or subcutaneous useInitial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-prescription
SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations.
- generic_name
- anifrolumab-fnia
- product_names
- Anifrolumab-fnia
- ndc
- 0310-3080, 0310-3040, 0310-3040-00, 0310-3080-25, 0310-3080-01, 0310-3080-95, 0310-3080-75, 0310-3080-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en